EZR and neoplasm: To investigate the possibility that there is a downregulation of tumor suppressors during L1-mediated CRC development, the signaling by the L1–ezrin–NF-κB pathway was inhibited in L1-overexpressing cells, using an shRNA against ezrin [6].